C

CALERI F.

Last name: CALERI F.

2021 (v1)

Publication

Metadata-only

A real-world study of alemtuzumab in a cohort of Italian patients

Russo C. V. Sacca F. Frau J.

Background and purpose: Real-world data on alemtuzumab are limited and do not provide evidence of its effectiveness after various disease-modifying therapies (DMTs). Our aim was to provide real-world data on the impact of clinical variables and previous DMTs on clinical response to alemtuzumab. Methods: Sixteen Italian multiple sclerosis...

Uploaded on: April 14, 2023
2022 (v1)

Publication

Metadata-only

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

Sormani M. P. Schiavetti I. Inglese M.

Background: In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS (pwMS) under different DMTs and to identify correlates of reduced protection. Methods: This is a prospective Italian multicenter cohort study, long-term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis)...

Uploaded on: April 14, 2023